Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Facioscapulohumeral muscular dystrophy.

Rabi Tawil1

  • 1Department of Neurology, University of Rochester School of Medicine and Dentistry, 601 Elmwood Avenue, Box 673, Rochester, NY 14642-8673, USA. rabi_tawil@urmc.rochester.edu

Current Neurology and Neuroscience Reports
|December 20, 2003
PubMed
Summary

Facioscapulohumeral muscular dystrophy (FSHD) is a genetic disorder. While a deletion on chromosome 4q35 is linked to FSHD, the exact molecular cause affecting gene expression remains unclear.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Plasma EV Proteomics Identifies ECM Remodeling and Inflammatory Proteins LUM and C7 as Candidate Biomarkers in FSHD.

Annals of clinical and translational neurology·2026
Same author

Late-onset facioscapulohumeral muscular dystrophy defines a distinct clinical subgroup.

Neuromuscular disorders : NMD·2026
Same author

Electrical Impedance Myography Detects Disease Progression over 12 to 24 Months in Facioscapulohumeral Muscular Dystrophy.

Annals of neurology·2026
Same author

A randomized, double-blind, placebo-controlled study of losmapimod in patients with facioscapulohumeral muscular dystrophy: Results of the REACH study.

Journal of neuromuscular diseases·2026
Same author

Electrical impedance myography captures features of muscle structure measured by MRI and transcriptomic analysis in facioscapulohumeral muscular dystrophy.

Journal of neuromuscular diseases·2025
Same author

SMCHD1 maintains heterochromatin, genome compartments and epigenome landscape in human myoblasts.

Nature communications·2025

Area of Science:

  • Genetics
  • Molecular Biology
  • Neurology

Background:

  • Facioscapulohumeral muscular dystrophy (FSHD) is an autosomal dominant inherited neuromuscular disorder.
  • FSHD presents with a characteristic pattern of muscle weakness, primarily affecting the face, shoulder girdle, and upper arms.
  • A deletion on chromosome 4q35 has been identified as the genetic cause of FSHD, but the underlying molecular mechanisms are not fully understood.

Purpose of the Study:

  • To elucidate the molecular pathophysiology of FSHD.
  • To investigate how the 4q35 deletion influences gene expression at a distance.
  • To explore potential mechanisms mediating the distant effects of the FSHD-associated deletion.

Main Methods:

  • Analysis of genetic alterations on chromosome 4q35.
  • Gene expression profiling in FSHD patients.
  • Investigating epigenetic modifications and long-range regulatory interactions.

Main Results:

  • The FSHD-associated deletions on chromosome 4q35 do not directly involve expressed genes.
  • Evidence suggests that the deletion impacts the expression of genes located elsewhere.
  • Recent studies propose potential mechanisms for this distant regulatory influence.

Conclusions:

  • The molecular basis of FSHD involves a disruption of gene regulation rather than a direct gene defect at the deletion site.
  • Understanding these distant regulatory effects is crucial for deciphering FSHD pathophysiology.
  • Further research into the proposed mechanisms may reveal novel therapeutic targets for FSHD.

Related Experiment Videos